Ips Research Company

1. Allergan Inc. $1,645,968 207 payments
2. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,410,119 21 payments
3. Eli Lilly and Company $1,167,399 20 payments
4. Janssen Research & Development, LLC $401,379 64 payments
5. Eisai Inc. $214,583 124 payments
6. Purdue Pharma L.P. $152,176 9 payments
7. Teva Pharmaceuticals USA, Inc. $146,517 24 payments
8. AbbVie, Inc. $136,951 42 payments
9. Ironwood Pharmaceuticals, Inc $97,468 23 payments
10. Hikma Pharmaceuticals USA $93,014 6 payments

1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,053,178 6 payments
2. A Phase 1B, Multicenter, Open-Label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Centanafadine Extended-Release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention Deficit/Hyperactivity Disorder $405,044 1 payment
3. A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder $263,061 11 payments
4. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $248,721 15 payments
5. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $241,354 27 payments
6. A Phase 1B, Multicenter, Open-Label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Centanafadine Extended-Release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-Deficit/Hyperactivity Disorder $224,422 1 payment
7. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $202,165 119 payments
8. A Phase 1B, Multicenter, Open-Label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Extended-Release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention Deficit Hyperactivity Disorder $175,065 1 payment
9. An open-label, multicenter, multiple-dose, safety and tolerability study of Adhansia XR extended-release capsules in children 4 to 12 years of age $152,176 9 payments
10. Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) $147,006 19 payments

1. Other $4,473 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.